Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 5

History repeats itself: horse originated hyperimmune sera production against SARS CoV-2

Pages
2263–2273
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In further studies, new purification methods can be used to increase the efficiency of the final product.Key words: Antibody cocktail, F(ab')2, hyperimmune sera, horse sera, immunoglobulin, SARS-CoV-2

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: SARS-CoV-2 disease was announced as a pandemic by The World Health Organization in early 2020.
📊
Key Findings & Data:Here, we aimed to produce hyperimmune sera that contain immunoglobulin G and F(ab')2 fragments sourced from horse antibodies as an urgent response to the pandemic.
💡
Conclusion & Impact:In further studies, new purification methods can be used to increase the efficiency of the final product.Key words: Antibody cocktail, F(ab')2, hyperimmune sera, horse sera, immunoglobulin, SARS-CoV-2
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Abstract

Background/aim: SARS-CoV-2 disease was announced as a pandemic by The World Health Organization in early 2020. It is still threatening the world population. Here, we aimed to produce hyperimmune sera that contain immunoglobulin G and F(ab')2 fragments sourced from horse antibodies as an urgent response to the pandemic. Materials and methods: SARS-CoV-2 was produced and inactivated with three different methods [formaldehyde (FA), formaldehyde, and binary ethylene amine (FA + BEI), and heat treatment]. After in vitro inactivation control, immunogens were mixed with Freund’s adjuvant, thereafter horses (n: 2 for FA, 4 for FA + BEI, 2 for heat inactivation) and New Zealand rabbits (n: 6 for FA, 6 for FA + BEI, 6 for heat inactivation) were immunized four times. Neutralizing antibody levels of the sera were measured at the 4th, 6th, and 8th weeks. When the antibodies were detected at the peak level, plasma was collected from horses and hyperimmune sera procured after the purification process. Results: Horses and rabbits produced highly neutralizing antibodies against the SARS-CoV-2 in FA and FA + BEI inactivation groups, foreign proteins were removed effectively after purification. Conclusion: This study presents a profitable practice to develop specific antisera in horses against SARS-CoV-2 for emergency and low-cost response. In further studies, new purification methods can be used to increase the efficiency of the final product.Key words: Antibody cocktail, F(ab')2, hyperimmune sera, horse sera, immunoglobulin, SARS-CoV-2

🔖

Cite This Article

YILDIRIM, Ö., EKİCİ, H., YARALI, C., ÜLKER, U., SARPER, M., KARDOĞAN, Ö., SARI, Ü. S., ÇAKIR, Ş., ÇALIŞKAN, E., DÜLGER, D., KABAKLI, Ö., SEZGİN, Y., HACIOĞLU, S., DANYER, E., KURT, Z. E., TAŞKAYA, H., ÜNDAR, B., ERGİN, G., TAÇBAŞ, E., BÜLBÜL, R., Mu, M. (2022). History repeats itself: horse originated hyperimmune sera production against SARS CoV-2. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 5, 2263–2273. https://ajindex.com/articles/609910

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Ku Z, Ye X, Salazar GT, Zhang N, An Z. Antibody therapies for the treatment of COVID-19. Antibody Therapeutics 2020; 3 (2): 101- 108. doi: 10.1093/abt/tbaa007 2. Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K et al. REGNCOV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 2020; 370 (6520): 1110- 1115. doi: 10.1126/science.abe2402 3. Costa Da CBP, Martins J. F, Luis E.R, Da Cunha NAR, Paula RC de, Castro HC. COVID-19 and hyperimmune sera: a feasible plan B to fight against coronavirus. International Immunopharmacology 2021; 90: 107220. doi: 10.1016/j.intimp.2020.107220 4. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 2020; (369) 6506: 1014-1018. doi: 10.1126/science.abd0831 5. Sharun K, Tiwari R, Iqbal Yatoo M, Patel SK, Natessan S et al. Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects. Expert Opinion Biological Therapy 2020; 20 (9): 1033-1046. doi: 10.1080/14712598.2020.1796963 6. Lee WT, Girardin RC, Dupuis AP, Kulas KE, Payne AF et al. Neutralizing antibody responses in COVID-19 convalescent sera. Journal of Infectious Diseases 2020; 1: 47-55. doi: 10.1093/infdis/jiaa673 7. Tiberghien P, De Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang 2020; 115 (6): 488- 494. doi: 10.1111/vox.12926 8. Luttenberger F. Excellence and Chance: The Nobel Prize Case of E. von Behring and É. Roux. History and Philosophy of Life Sciences 1996; 18 (2): 225-239. 9. Çizmen F. Introduction. Journal of Etlik Veterinary Microbiology 1960; 1 (1): 6-9. 10. Lu JH, Guo ZM, Han WY, Wang G, Zhang D et al. Preparation and development of equine hyperimmune globulin F(ab’)2 against severe acute respiratory syndrome coronavirus. Acta Pharmacologica Sinica 2005; 26 (12): 1479-1484. doi: 10.1111/j.1745-7254.2005.00210.x 11. Zhao G, Ni B, Jiang H, Luo D, Pacal M et al. Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters. Viral Immunology 2007; 20 (1): 197-205. doi: 10.1089/vim.2006.0064 12. Zhao Y, Zheng X, He S, Li S, Wang W et al. Equine immunoglobulin F (ab′)2 fragments protect mice from Rift Valley fever virus infection. International Immunopharmacology 2018; 64: 217-222.